Rectal Neoplasms Clinical Trial
Official title:
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Verified date | April 2020 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to participants treated with IV cetuximab + irinotecan. The primary hypothesis is that administration of dalotuzumab in combination with irinotecan to participants with wild-type KRAS metastatic rectal carcinoma with high insulin growth factor (IGF)-1/low IGF-2 expression levels improves progression-free survival compared to patients treated with cetuximab in combination with irinotecan.
Status | Terminated |
Enrollment | 11 |
Est. completion date | December 9, 2014 |
Est. primary completion date | December 9, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Has metastatic colorectal cancer with primary tumor originating from the rectum - Has an available archival (recent or remote) tumor, or newly obtained formalin-fixed tissue available for analysis for biomarker studies - Has at least one measurable lesion greater than or equal to 10 mm - Disease has progressed after treatment with both irinotecan- and oxaliplatin-containing regimens and should have progressed on or within 3 months of completing their last line of therapy - Has a performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale Exclusion Criteria: - Has poorly-controlled diabetes - Has received chemotherapy or biological therapy within 2 weeks prior to initial dosing on this study, or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline, or who is within 3 weeks from a prior surgery - Has received radiotherapy within 2 weeks prior to initial dosing on this study, unless the radiotherapy was for management of pain - Is currently participating or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the investigational agent, whichever is longer, of initial dosing on this study - Was unable to complete previous course of irinotecan due to intolerable toxicity, other than discontinuation due to fatigue following prolonged administration (>4 months exposure) - Has prior exposure to insulin-like growth factor 1 receptor (IGF-1R) inhibitors or epidermal growth factor receptor (EGFR) inhibitors - Has a known central nervous system (CNS) metastases and/or carcinomatous meningitis - Has primary CNS tumor - Has a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma; potentially curative therapy with no evidence of that disease for 5 years, deemed low risk for recurrence by treating physician. - Is human immunodeficiency virus (HIV)-positive - Has active hepatitis B or C infection and is receiving antiviral treatment regimens - Has symptomatic ascites or pleural effusion - Is concurrently using growth hormone (GH), or growth hormone inhibitors |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of Progression-free Survival (PFS) | PFS is a measure of the time from randomization to the time of first documented disease progression (assessed by an independent Radiology Review Committee [iRRC]) or participant death, whichever occurs first. | From randomization (Cycle 1, Day 1) to the first documented disease progression or death due to any cause, whichever occurs first (up to 3 years) | |
Secondary | Percentage of Participants With Objective Response Rate (ORR) | ORR is defined as the percentage of participants achieving a complete response (CR) or partial response (PR) during the course of the study using enhanced Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Confirmation of response was not required. | From randomization (Cycle 1, Day 1) to the first documented disease progression or death due to any cause, whichever occurs first (up to 3 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537340 -
PET/MR for Staging Rectal Cancer Patients With and Without EMVI-MR
|
||
Recruiting |
NCT02565667 -
A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler
|
N/A | |
Terminated |
NCT02538913 -
Exercise Training for Rectal Cancer Patients
|
N/A | |
Not yet recruiting |
NCT02439086 -
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
|
N/A | |
Completed |
NCT02233374 -
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
|
N/A | |
Completed |
NCT00535652 -
Concentration of Ertapenem in Colorectal Tissue
|
Phase 4 | |
Completed |
NCT00535041 -
Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA
|
N/A | |
Recruiting |
NCT04949646 -
Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision
|
N/A | |
Recruiting |
NCT04095468 -
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
|
||
Recruiting |
NCT06017583 -
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT05689775 -
Reconstruction After Abdominoperineal Resection With Robot-assisted Harvest of VRAM Flap
|
||
Recruiting |
NCT04006951 -
Development of a Clinical and Biological Database in Rectum Cancer
|
N/A | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03714490 -
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03325361 -
The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage
|
N/A | |
Completed |
NCT02252250 -
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
|
N/A | |
Completed |
NCT04455737 -
Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision
|
||
Completed |
NCT01816607 -
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
|
||
Completed |
NCT01721785 -
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT01171300 -
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
|
N/A |